It appears that in HER2-low BC, HER2 molecules on the tumor cell surface primarily function as a means for delivering antibody conjugated drugs, instead of direct inhibition of HER2 dimerization or the blockade of downstream signaling [15]. The gene discussed is ERBB2; the disease is breast cancer.